| Date | Title | Description |
| 22.07.2025 | BiomEdit Forges New Path in Animal Health with Major Advances and Strategic Funding | BiomEdit, a leading animal health biotechnology firm, announced major advancements. Its pioneering poultry solution, BE-101 (Optavant™), a non-antibiotic treatment for necrotic enteritis in broiler chickens, entered the final USDA condition... |
| 18.07.2025 | BiomEdit: Over $20 Million Raised For Animal Health Biotechnology Platform | BiomEdit, an innovative animal health biotechnology company, has achieved a significant milestone with its lead candidate, BE-101, which is designed to prevent mortality from necrotic enteritis (NE) in broiler chickens. The product is now i... |
| 16.07.2025 | BiomEdit Advances First-of-Its-Kind Engineered Bacteria Product to Final Development Phase, Secures Series B Funding, Adds Key Industry Leadership | BiomEdit logo
Poultry industry's first engineered probiotic biologic moves into final development and regulatory stages for USDA conditional licensure and commercial scale-up
GREENFIELD, Ind., July 16, 2025 /PRNewswire-PRWeb/ -- BiomEdit, a... |
| 16.07.2025 | BiomEdit raises $18.4m Series B to expand designer probiotics platform | Indiana-based animal microbiome specialist BiomEdit has raised an $18.4 million Series B round and is gearing up to launch its first product, an engineered probiotic (BE-101) to tackle necrotic enteritis, a bacterial affliction driving sign... |